Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Anaxis Pharma patents MLKL inhibitors

Jan. 12, 2022

Dysregulation of the tRNA synthetase modulator NOTCH1 behind T-ALL pathogenesis

Jan. 12, 2022

Betta Pharmaceuticals discloses new HIF-2alpha inhibitors

Jan. 11, 2022

Regulation of SWI/SNF complex SMARCA2/4 subunits for treating enhancer-addicted prostate cancer

Jan. 11, 2022

Volastra Therapeutics identifies ENPP1 inhibitors

Jan. 10, 2022

Incyte synthesizes new JAK2 V617F inhibitors

Jan. 10, 2022

Gossamer Bio presents DGKA and/or DGKZ inhibitors

Jan. 10, 2022

Tucatinib plus anti-HER2 antibody NSCs prolong survival of mice with brain-metastatic breast cancer

Jan. 10, 2022

Indirect radiolabeling of pGlu for intratumoral delivery of alpha- and beta-particle emitters

Jan. 10, 2022

LA-PAMAM/pmiR-218 polyplex as potential targeted gene therapy against HCC

Jan. 7, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...